THE INFLAMMATORY MEDIATORS IN THE PATHOGENESIS OF METABOLIC SYNDROME
*Aripova T. U., Ismailova A. A., Kasimova M. S., Rozumbetov R. J., Petrova T. A., Rakhimjanov A. A., Alimova D. B. and Akbarov U. S.
The article presents the results of a study of serum levels of IL-6, TNF-α and C-reactive protein (CRP) in patients with metabolic syndrome before and after treatment with rosuvastatin. The study included 20 patients with MS and impaired immune status indicators from 39 to 68 years old (average age 56.8 ± 1.7 years). Patients were prescribed lipid-lowering therapy (rosuvastatin) at 10 mg. The collection of patients was carried out on the basis of the "Immunogen-test" RDC on an outpatient basis and included observation in the dynamics of treatment after 3 months. The cytokines IL-6 and TNF-α were determined in blood serum by the enzyme immunoassay using the reagent kits of Vector-Best CJSC (Novosibirsk, Russia) on an enzyme-linked immunosorbent analyzer StatFax - 2100 (USA). Conclusions: In patients with unstable patients with MS, the dynamics of treatment with rosuvastatin showed a significant decrease in blood lipids: total cholesterol by 1.5 times (p <0.001), triglycerides by 1.5 times (p <0.01), low-density lipoprotein cholesterol in 1.8 times (p <0.001), and the atherogenic coefficient was 1.6 times (p <0.001). In addition, the anti-inflammatory effect of rosuvastatin was noted, namely, a significant decrease in the markers of inflammation of CRP by 2 times (p <0.01), IL-6 by 3 times (p <0.001), TNF-a by 2.1 times (p <0,01). The results of our study showed that the applied lipid-lowering therapy significantly reduced the level of not only lipids but also pro-inflammatory cytokines, which in turn confirms their pleiotropic (anti-inflammatory) effect.
[Full Text Article]